SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary

Endocrine-Related Cancer

Volumn 22, Issue 1, 2015, Pages 111-119

  Lee, Misu ^a   Lupp, Amelie ^b   Mendoza, Nigel ^c   Martin, Niamh ^d   Beschorner, Rudi ^e   Honegger, Jürgen ^e   Schlegel, Jürgen ^f   Shively, Talia ^d   Pulz, Elke ^a   Schulz, Stefan ^b   Roncaroli, Federico ^d   Pellegata, Natalia S ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Aggressive adenoma; Gonadotroph adenoma; Pasireotide; Somatostatin receptors

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE; PASIREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG TARGETING; FEMALE; GONADOTROPH ADENOMA; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DENSITY; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RECURRENCE; ADENOMA; ANALOGS AND DERIVATIVES; GENETICS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; PITUITARY NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; PITUITARY NEOPLASMS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; YOUNG ADULT;

EID: 84923543576     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0472     Document Type: Article

References (29)

1. Ben-Shlomo A & Melmed S 2008 Somatostatin agonists for treatment of acromegaly. Molecular and Cellular Endocrinology 286 192-198. (doi:10.1016/j.mce.2007.11.024)
2. Berkmann S, Schlaffer S, Nimsky C, Fahlbusch R & Buchfelder M 2014 Follow-up and long-term outcome of nonfunctioning pituitary adenoma operated by transsphenoidal surgery with intraoperative high-field magnetic resonance imaging. Acta Neurochirurgica 156 2233-2243. (doi:10.1007/s00701-014-2210-x)
3. Brochier S, Galland F, Kujas M, Parker F, Gaillard S, Raftopoulos C, Young J, Alexopoulou O, Maiter D & Chanson P 2010 Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. European Journal of Endocrinology 163 193-200. (doi:10.1530/EJE-10-0255)
4. Colao A, Grasso LF, Pivonello R & Lombardi G 2011 Therapy of aggressive pituitary tumors. Expert Opinion on Pharmacotherapy 12 1561-1570. (doi:10.1517/14656566.2011.5)
5. Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM et al. 2012 A 12-month phase 3 study of pasireotide in Cushing's disease. New England Journal of Medicine 366 914-924. (doi:10.1056/NEJMoa1105743)
6. Cuevas-Ramos D & Fleseriu M 2014 Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. Journal of Molecular Endocrinology 52 R223-R240. (doi:10.1530/JME-14-0011)
7. Duran-Prado M, Gahete MD, Martinez-Fuentes AJ, Luque RM, Quintero A, Webb SM, Benito-Lopez P, Leal A, Schulz S, Gracia-Navarro F et al. 2009 Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. Journal of Clinical Endocrinology and Metabolism 94 2634-2643. (doi:10.1210/jc.2008-2564)
8. Eigler T, Ben-Shlomo A, Zhou C, Khalafi R, Ren SG & Melmed S 2014 Constitutive somatostatin receptor subtype-3 signaling suppresses growth hormone synthesis. Molecular Endocrinology 28 554-564. (doi:10.1210/me.2013-1327)
9. Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S, Culler MD, Pfeffer U, Noonan DM, Schettini G et al. 2003 Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 144 1574-1584. (doi:10.1210/en.2002-220949)
10. Gatto F, Feelders RA, van der Pas R, Kros JM, Waaijers M, Sprij-Mooij D, Neggers SJ, van der Lelij AJ, Minuto F, Lamberts SW et al. 2013 Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism 98 E66-E71. (doi:10.1210/jc.2012-2609)
11. Grozinsky-Glasberg S, Shimon I, Korbonits M & Grossman AB 2008 Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocrine-Related Cancer 15 701-720. (doi:10.1677/ERC-07-0288)
12. Korner M, Waser B, Schonbrunn A, Perren A & Reubi JC 2012 Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. American Journal of Surgical Pathology 36 242-252. (doi:10.1097/PAS.0b013e31823d07f3)
13. Lee M, Marinoni I, Irmler M, Psaras T, Honegger JB, Beschorner R, Anastasov N, Beckers J, Theodoropoulou M, Roncaroli F et al. 2013 Transcriptome analysis of MENX-associated rat pituitary adenomas identifies novel molecular mechanisms involved in the pathogenesis of human pituitary gonadotroph adenomas. Acta Neuropathologica 126 137-150. (doi:10.1007/s00401-013-1132-7)
14. Lloyd RJ, Kovacs K, Young WF Jr, Farrell WE, Asa SL, Trouillas J, Kontogeorgos G, Sano T, Scheithauer BW, Horvath E et al. 2004 Tumours of the pituitary gland. In Pathology and Genetics, pp 9-48. eds RA DeLellis, RV Lloyd & PU Heitz. Lyon: International Agency for Research and Cancer (IARC).
15. 3 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-5. Neuroendocrinology 96 301-310. (doi:10.1159/000337659)
16. Mor E, Rodi IA, Bayrak A, Paulson RJ & Sokol RZ 2005 Diagnosis of pituitary gonadotroph adenomas in reproductive-aged women. Fertility and Sterility 84 757.e1-757.e6. (doi:10.1016/j.fertnstert.2005.02.050)
17. Nielsen S, Mellemkjaer S, Rasmussen LM, Ledet T, Olsen N, Bojsen-Moller M, Astrup J, Weeke J & Jorgensen JO 2001 Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo. Journal of Endocrinological Investigation 24 430-437. (doi:10.1007/BF03351043)
18. Ntali G, Capatina C, Grossman A & Karavitaki N 2014 Functioning gonadotroph adenomas. Journal of Clinical Endocrinology and Metabolism 99 4423-4433. (doi:10.1210/jc.2014-2362)
19. Pawlikowski M, Pisarek H, Kunert-Radek J & Radek A 2003 Immunohisto-chemical detection of somatostatin receptor subtypes in "clinically nonfunctioning" pituitary adenomas. Endocrine Pathology 14 231-238. (doi:10.1007/s12022-003-0015-1)
20. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ et al. 2010 Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. Journal of Clinical Endocrinology and Metabolism 95 2781-2789. (doi:10.1210/jc.2009-2272)
21. Pisarek H, Pawlikowski M, Kunert-Radek J & Radek M 2009 Expression of somatostatin receptor subtypes in human pituitary adenomas - immunohistochemical studies. Endokrynologia Polska 60 240-251.
22. Pisarek H, Kunert-Radek J, Radek M, Swietoslawski J, Winczyk K & Pawlikowski M 2011 Expression of somatostatin receptor subtypes in primary and recurrent gonadotropinomas: are somatostatin receptors involved in pituitary adenoma recurrence? Neuro Endocrinology Letters 32 96-101.
23. Ramirez C, Cheng S, Vargas G, Asa SL, Ezzat S, Gonzalez B, Cabrera L, Guinto G & Mercado M 2012 Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. Journal of Clinical Endocrinology and Metabolism 97 1745-1751. (doi:10.1210/jc.2011-3163)
24. Schmid HA & Schoeffter P 2004 Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80 (Suppl 1) 47-50. (doi:10.1159/000080741)
25. Theodoropoulou M & Stalla GK 2013 Somatostatin receptors: from signaling to clinical practice. Frontiers in Neuroendocrinology 34 228-252. (doi:10.1016/j.yfrne.2013.07.005)
26. Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T et al. 2013 A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years postoperative follow-up. Acta Neuropathologica 126 123-135. (doi:10.1007/s00401-013-1084-y)
27. Webb SM, Ware JE, Forsythe A, Yang M, Badia X, Nelson LM, Signorovitch JE, McLeod L, Maldonado M, Zgliczynski W et al. 2014 Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease. European Journal of Endocrinology 171 89-98. (doi:10.1530/EJE-13-1013)
28. Young WF Jr, Scheithauer BW, Kovacs KT, Horvath E, Davis DH & Randall RV 1996 Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 cases. Mayo Clinic Proceedings 71 649-656. (doi:10.1016/S0025-6196(11)63002-4)
29. Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M et al. 2007 Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endo-thelial growth factor secretion. Endocrine-Related Cancer 14 91-102. (doi:10.1677/ERC-06-0026)